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Abstract. – OBJECTIVE: Although some pre-
vious meta-analyses have demonstrated a rela-
tionship between statin therapy and all-cause 
mortality in patients with chronic kidney dis-
ease (CKD), conflicting results have been re-
ported. Thus, we performed an umbrella review 
to understand the strength of evidence and va-
lidity of the claimed associations between sta-
tin use and all cause and cardiovascular mor-
tality in CKD patients, including patients on di-
alysis (CKD stage 5D) and transplant recipients. 
MATERIALS AND METHODS: We compre-
hensively re-analyzed the data of 14 meta-anal-
yses of observational studies and randomized 
controlled trials on associations between sta-
tin use and different CKD groups – CKD, CKD 
stage 5D, and kidney transplant recipients. We 
also assessed the strength of evidence of the 
re-analyzed outcomes, which were determined 
from the criteria, including the statistical signif-
icance of the p-value of random-effects, as well 
as fixed-effects meta-analyses, small-study ef-
fects, between-study heterogeneity, and a 95% 
prediction interval. 
RESULTS: For CKD patients, statin use 
showed suggestive evidence for an associa-
tion with reduced all-cause mortality [relative 
risk (RR) 0.77, 95% confidence interval (0.69-
0.87)]. For kidney transplant recipients, statin 
use showed suggestive evidence for an associ-
ation with reduced cardiovascular mortality [RR 
0.67, 95% CI (0.50-0.90)]. However, for patients 
on dialysis, statins showed neither cardiovas-
cular [RR 0.93, 95% CI (0.86-1.01)] nor all-cause 
mortality [RR 0.98, 95% CI (0.89-1.08)] benefits.
CONCLUSIONS: Our finding indicates that 
statin could improve all-cause and cardiovascu-
lar mortality in patients with non-dialysis CKD.
Key Words:
CKD, Mortality, Statin, Umbrella review. 
Introduction
Chronic kidney disease (CKD) affects up to 
16% of the world’s population1. It is often asso-
ciated with debilitating morbidity and mortality, 
including but not limited to leading non-com-
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municable diseases, such as cardiovascular dis-
eases and kidney failure. CKD contributes to the 
dreadful economic burden: its ever-increasing in-
cidence, the economic burden it creates on society, 
and the financial strain it puts on healthcare sys-
tems have led CKD to be recognized as one of the 
most crucial public health emergencies of the 21st 
century2,3. Globally, it represents the 16th leading 
disease cause of the most years-of-life-lost and was 
responsible for a 33.7% increase in all-age deaths 
between 2007 and 20171,4. CKD is defined as an 
alteration in either the renal structure, function, 
or both for a period of at least three months with 
implications on the person’s health. This alteration 
usually leads to a fall in the glomerular filtration 
rate, below 60 mL/min/1.73 m2, or albuminuria 
of more than 30 mg per day5. The causes of CKD 
are often diverse, but obesity, hypertension, and/
or diabetes mellitus are major risk factors for both 
cardiovascular disease and CKD6. 
With the aging of the global population and the 
projected increase in the incidence of non-com-
municable diseases, such as obesity and diabetes, 
the prevalence of CKD is expected to increase 
even further7-9. The mortality rate among CKD 
patients is estimated to be 1.4 to 3.7-fold that in 
patients without CKD10. 
Statins are a group of inhibitors of 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase used in preventing coronary 
heart disease by lowering plasma cholesterol11. 
Statin-based regimens have long been consid-
ered a component of the mainstay treatment for 
CKD patients. Most meta-analyses and post-
hoc analyses have reported a benefit in using 
statin in decreasing all-cause mortality among 
people living with CKD12-14. However, recent 
prospective studies on statins challenged this 
anticipated beneficial effect on mortality among 
CKD patients10. 
To determine and assess the strength of the 
evidence of the effect of statins on the reduction 
of mortality in patients with CKD, we carried 
out an umbrella review and comprehensively 
re-analyzed the data of meta-analyses of random-
ized controlled trials (RCTs) and observational 
studies.
Materials and Methods
We conducted an umbrella review of me-
ta-analyses and systematic reviews studying the 
effects and associations between statin use and 
the all-cause mortality in patients with CKD 
across the different stages of the disease. We 
performed this umbrella review per the Preferred 
Reporting Items for Systematic Reviews and Me-
ta-Analyses (PRISMA) guidelines. 
Literature Search
We performed our search using the following 
keywords: ‘(hydroxymethyl glutaryl-coa reduc-
tase inhibitor OR statin) AND (mortality OR 
chronic kidney disease) AND (meta-analysis 
OR systematic review)’. We limited our search 
to articles written in English. We performed 
the search in January 2020. We sought for me-
ta-analyses of either RCTs or observational stud-
ies in our search strategy. Each retrieved article 
was reviewed in detail, from the title, through 
the abstract, to the full texts. Subsequently, 
we used inclusion and exclusion criteria in the 
decision to include the articles or not. We also 
conducted a supplementary EMBASE database 
search for completion. Eligible meta-analyses 
that did not overlap with the PubMed search 
were included. 
Eligibility Criteria and Data Extraction
Meta-analyses and systematic reviews of both 
RCTs and observational studies (cohort and 
case-control studies) investigating the association 
between statin use and mortality rates of CKD 
patients were included. We added articles con-
taining multiple meta-analyses and independent-
ly assessed each separate meta-analysis for inclu-
sion. Review articles, in-vitro studies, and genetic 
studies were excluded. 
Two of our investigators (G.H.J. and J.I.S) 
individually performed data search and ex-
traction. Discrepancies were resolved via con-
sensus. We gathered information regarding the 
articles’ first author, year of publication, CKD 
stages, study design, number of included stud-
ies, mortality rates, total number of partici-
pants, and the random-effects with a 95% con-
fidence interval (CI). We analyzed the raw data 
of each study considering all data on mortality 
rates of CKD patients, statins use, and study 
design. We reported the results of articles con-
taining both RCTs and observational studies 
separately.
Statistical Analysis
We analyzed each meta-analysis that satisfied 
the inclusion criteria and reported the association 
between statin use and mortality among CKD 
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patients. In the case of overlapping meta-analy-
ses, we combined the individuals according to 
mortality, CKD, and study design. In this case, 
we conducted a re-meta-analysis after eliminat-
ing overlapping studies. The summary effect size 
was reported with a 95% CI and p-value with both 
random-effects and fixed-effects. All re-analyses 
in this study were performed using the Com-
prehensive Meta-Analysis software ver.3.3.070 
(Borenstein, NH, USA).
Estimation of Summary Effects and 
Estimation of Prediction Interval
All individual studies were re-examined for 
each meta-analysis. We assessed the summary 
effects and 95% CI using both random- and 
fixed-effects methods. We also reported the 95% 
prediction interval (PI), which tackles the disper-
sion of effects and additionally takes into account 
the in-between-study heterogeneity. Our CI re-
flected the accuracy of the mean.
Evaluation of Between-Study 
Heterogeneity and Small-Study Effects
We used the I2 metric of inconsistency and 
the p-value of the X2-based Cochrane Q test to 
assess heterogeneity across the studies. I2 val-
ues of <50% (low), 50%-75% (moderate), and 
>75% (high) were used to describe heterogeneity. 
Egger’s regression test was used to interpret the 
publication biases. Small-study effects were used 
for detecting publication and reporting bias. We 
considered an article to have a small-study when 
Egger’s test had a p-value < 0.10 in random-ef-
fects meta-analyses.
Determination of the Level of Evidence
The level of the evidence of the association 
between statin use and mortality among CKD 
patients was determined for each meta-analysis 
and re-analyzed based on the pooled meta-anal-
ysis. The criteria were based on several factors, 
including: the statistical significance by random 
and fixed-effects p-values, 95% PI, small-study 
effects, between-study heterogeneity, and con-
cordance between the effect estimate of the most 
extensive study and a summary estimate of the 
meta-analysis. 
The Criteria Were Stratified as Follows:
Convincing evidence: (1) Statistical signifi-
cance for the random effect and fixed effect 
p-values at p < 0.001, (2) no small-study effects 
or large between-study heterogeneity, (3) the 95% 
PI rejected the null hypothesis, (4) concordance 
between the effect estimate of the largest study 
and the summary effect of the random effects 
meta-analysis.
Suggestive evidence: (1) Statistical significance 
of random effects at p < 0.05, (2) the 95% PI in-
cluded the null hypothesis, (3) no small-study 
effects or large between-study heterogeneity.
Weak evidence: (1) Statistical significance of 
random effects at p < 0.05, (2) small-study 
effects, or large between-study heterogeneity 
found.
Non-significant association: there was no statis-
tical significance by random effect meta-anal-
ysis (p > 0.05).
When significant heterogeneities were en-
countered, the results were reassessed to re-
solve whether heterogeneities were secondary 
to differences in the direction of the effect or if 
it could be due to differences in the size of the 
association (level of evidence recalculated in the 
latter case).
Results
Search Strategy and Selected 
Studies for Reanalysis
136 potentially eligible articles were retrieved 
by the literature search. After that, a stepwise 
screening was performed. Forty-eight articles 
were excluded (35 were duplicates and 13 were 
not meta-analysis) after assessing the titles, and 
forty-four articles were screened by the abstracts 
(23 were not investigating statin therapy, 7 were 
not including kidney disease patients, and 1 was 
high intensity statin therapy). Finally, after re-
viewing another 57 full-text articles for eligibil-
ity, 43 were excluded because they did not have 
a mortality outcome. The eligible 14 articles de-
scribing the associations or relationships between 
statin use and mortality or survival of CKD pa-
tients were finally included15-28.
The outcomes evaluated in the meta-analyses 
included all-cause mortality and cardiovascular 
mortality of CKD patients (defined as ‘not on 
dialysis’), CKD 5D (defined as ‘on dialysis’), 
and of kidney transplant recipients (Tables I-VI). 
Eight (57%) of the 14 meta-analyses examined 
all-cause mortality, five (36%) examined cardio-
vascular mortality in CKD patients not receiving 
dialysis, seven (50%) studied all-cause mortality, 
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Table I. Effects of statin therapy in CKD patients (all-cause mortality).
 Author/       Effect Random Fixed  Egger’s I2 p-value p-value 95%
 year N T Type of patients N/T T/M Model* size* effect§ effect§ D/N/I p-value (p-value) (R) (F) PI S Evidence
Messow, 6 RCT CKD 7601/ HR Mixed 0.82 0.80 0.82 2/4/0 0.142 30.7 (0.205) 0.004 <0.001 0.55- No Suggestive
et al 2017    15288   (0.73- (0.68- (0.73-      1.14  
       0.91) 0.93) 0.91)        
Zhang,  11 RCT CKD 16160/ RR Fixed 0.78 0.65 0.75 4/7/0 0.183 71.0 (< 0.001) 0.001 < 0.001 0.31- No Weak
et al 2016    32557   (0.72- (0.50- (0.69-      1.35  
       0.84) 0.84) 0.81)        
Zhang, 7 RCT Mild to moderate 16722/ RR Random 0.79 0.79 0.79 4/3/0 0.252 6.3 (0.380) < 0.001 < 0.001 0.68- No Convincing
et al 2014    CKD 33589    (0.72- (0.72- (0.73-      0.90  
       0.86) 0.86) 0.85)        
Palmer,  10 RCT CKD not on dialysis 14063/ RR Random 0.79 0.79 0.81 4/6/0 0.294 31.7 (0.155) 0.001 < 0.001 0.58- No Suggestive
et al 2014     28276   (0.69- (0.69- (0.75-      1.06  
       0.91) 0.91) 0.87)        
Barylski,  9 RCT CKD not on dialysis 10274/ RR Random 0.86 0.86 0.99 3/5/1 0.009 78.9 (< 0.001) 0.023 0.701 0.59- Yes Weak
et al 2013     20898   (0.75- (0.75- (0.95      -1.04)  
       0.98) 0.98) 1.26        
Barylski,  5 RCT CKD not on dialysis 6942/ RR Fixed 0.66 0.64 0.67 3/2/0 0.338 35.1 (0.187) < 0.001 < 0.001 0.33- No Suggestive
et al 2013     13898    (0.55- (0.50- (0.56-      0.80)  
       0.79) 0.82) 1.23       
Navaneethan,  5 RCT CKD not on dialysis 9340/ RR Random 0.81 0.81 0.81 1/4/0 0.391 0.0 (0.774) < 0.001 < 0.001 0.70- No Convincing
et al 2009     18762    (0.74 (0.74- (0.74-      0.93  
       0.89) 0.89) 0.89)        
Strippoli,  5 RCT Pre-dialysis CKD 9049/ RR Random 0.81 0.81 0.81 1/4/0 0.391 0.0 (0.774) < 0.001 < 0.001 0.70- No Convincing
et al 2008     18176    (0.74 (0.74- (0.74-      0.93  
       0.89) 0.89) 0.89)        
Combined 15 RCT CKD not on dialysis – RR – – 0.77 0.80 6/9/0 0.202 36.3 (0.079) <0 .001 < 0.001 0.58- No Suggestive
Analysis        (0.69- (0.75-      1.02  
        0.87) 0.86)        
CKD, chronic kidney disease; D/N/I, decreasing risk/No difference/Increasing risk; F, fixed effect; HR, hazard ratio; N, number of studies; N/T, number of intervention/total; PI, prediction 
intervals; R, random effect; RCT, randomized controlled study; RR, risk ratio; S, small-study effect; T, type of studies; T/M, Type of metrics; *Value reported in the original article of the 
meta-analysis; §Value obtained from re-analysis of the original meta-analysis.
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Table II. Effects of statin therapy in CKD patients (cardiovascular mortality).
 Author/       Effect Random Fixed  Egger’s I2 p-value p-value 95%
 year N T Type of patients N/T T/M Model* size* effect§ effect§ D/N/I p-value (p-value) (R) (F) PI S Evidence
Zhang, 6 RCT Mild to moderate 9437/ RR Random 0.83 0.83 0.83 1/5/0 0.170 0.0 0.002 0.002 0.69- No Convincing
et al 2014    CKD 18974   (0.73- (0.73- (0.73-   (0.917)   0.98 
       0.93) 0.93) 0.93)        
Palmer,  6 RCT CKD not on 9480/ RR Random 0.77 0.77 0.77 1/5/0 0.096 0.0 (0.919) <0.001 <0.001 0.65- No Convincing
et al 2014    dialysis 19059    (0.69- (0.69- (0.69-      0.92  
       0.87) 0.87) 0.87)        
Barylski,  4 RCT CKD not on dialysis 2699/ RR Fixed 0.69 0.69 0.69 2/2/0 0.104 0.0 (0.859) 0.001 0.001 0.42- No Suggestive
et al 2013    5406    (0.55- (0.55- (0.55-      1.13  
       0.86) 0.87) 0.87)        
Navaneethan,  4 RCT CKD not on dialysis 9334/ RR Random 0.80 0.80 0.80 1/3/0 0.435 0.0 (0.810) < 0.001 < 0.001 0.61- No Suggestive
et al 2009     18746    (0.70- (0.70- (0.70-      1.05 
       0.90)  0.90) 0.90)       
Strippoli,  4 RCT Pre-dialysis CKD 9001/ RR Random 0.80 0.84 0.84 1/3/0 0.389 0.0 (0.815) 0.004 0.004 0.34- No Convincing
et al 2008     18085    (0.70- (0.74- (0.74-      0.58 
       0.90) 0.94) 0.94)       
Combined 10 RCT CKD not on dialysis - RR - - 0.80  0.80 3/7/0 0.036 0.0 (0.910) <0.001 <0.001 0.70- Yes Weak
Analysis        (0.72- (0.72-      0.90  
        0.88) 0.88)        
CKD, chronic kidney disease; D/N/I, decreasing risk/No difference/Increasing risk; F, fixed effect; N, number of studies; N/T, number of intervention/total; PI, prediction intervals; R, 
random effect; RCT, randomized controlled study; RR, risk ratio; S, small-study effect; T, type of studies; T/M, Type of metrics; *Value reported in the original article of the meta-analysis; 
§Value obtained from re-analysis of the original meta-analysis.
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Table III. Effects of statin therapy in CKD 5D patients (all-cause mortality).
 Author/       Effect Random Fixed  Egger’s I2 p-value p-value 95%
 year N T Type of patients N/T T/M Model* size* effect§ effect§ D/N/I p-value (p-value) (R) (F) PI S Evidence
Messow,  2 RCT CKD and dialysis 2008/ HR Mixed 0.95 0.95 0.95 0/2/0 NA 0.0 (0.744) 0.262 0.262 NA NA No
et al 2017     4028   (0.87- (0.87- (0.87-        evidence
       1.04) 1.04) 1.04)        
Yang,  5 RCT, Diabetic dialysis 6454/ HR Random 0.81 0.81 0.83 3/2/0 0.183 54.7 (0.065) 0.002 <0.001 0.56- No Weak
et al 2015   OS  13081    (0.71- (0.71- (0.78-      1.18  
       0.92) 0.92) 0.88)        
Sun,  3 RCT Dialysis 3541/ RR Fixed 0.98 0.98 0.98 0/3/0 0.404 0.0 (0.533) 0.410 0.410 0.65- No No
et al 2015     7051   (0.93- (0.93- (0.93-      1.46  evidence
       1.04) 1.03) 1.03)       
Palmer,  7 RCT Dialysis 2352/ RR Random 0.96 0.96 0.96 0/7/0 0.182 0.0 (0.869) 0.184 0.184 0.88- No No
et al 2013     4705    (0.90- (0.90- (0.90-      1.04  evidence
       1.02) 1.02) 1.02)        
Barylski,  3 RCT CKD and dialysis 3262/ RR Random 0.99 0.99 1.02 0/2/1 0.123 82.5 (0.003) 0.848 0.442 0.26- No Weak
et al 2013     6857   (0.88- (0.88- (0.97-      3.75  
       1.11) 1.11) 1.06)        
Navaneethan, 5 RCT Dialysis 928/ RR Random 0.95 0.95 0.95 0/5/0 0.303 0.0 (0.652) 0.349 0.349 0.80- No No
et al 2009    1884   (0.86- 0.86- (0.86-      1.13  evidence
       1.06) (1.06) 1.06)        
Strippoli,  3 RCT CKD and dialysis 696/ RR Random 0.95 0.95 0.95 0/3/0 0.046 0.0 (0.440) 0.372 0.372 0.47- Yes No
et al 2008    1404    (0.85- (0.85- (0.85-      1.91  evidence
       1.06) 1.06) 1.06)        
Combined 16 Comb- Dialysis – RR – – 0.93 0.96 3/12/1 0.135 70.1 (<0.001) 0.072 0.021 0.73- No No
Analysis   ined      (0.86- (0.93-      1.19  evidence
        1.01) 0.99)        
CKD, chronic kidney disease; D/N/I, decreasing risk/No difference/Increasing risk; F, fixed effect; HR, hazard ratio; N, number of studies; NA, not applicable; N/T, number of intervention/
total; OS; observational study; PI, prediction intervals; R, random effect; RCT, randomized controlled study; RR, risk ratio; S, small-study effect; T, type of studies; T/M, Type of metrics; 
*Value reported in the original article of the meta-analysis; §Value obtained from re-analysis of the original meta-analysis.
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Table IV. Effects of statin therapy in CKD 5D patients (cardiovascular mortality).
 Author/       Effect Random Fixed  Egger’s I2 p-value p-value 95%
 year N T Type of patients N/T T/M Model* size* effect§ effect§ D/N/I p-value (p-value) (R) (F) PI S Evidence
Messow,  2 RCT CKD and dialysis 2008/ HR Mixed 0.92 0.92 0.94 0/2/0 NA 52.6 0.409 0.342 NA NA No
et al 2017     4028   (0.75- (0.75- (0.82-   (0.146)     evidence
       1.13) 1.13) 1.07)        
Sun, et al 3 RCT Dialysis 3541/ RR Fixed 0.97 0.97 0.97 0/3/0 0.343 20.3 (0.285) 0.538 0.523 0.39- No No
2015     7051   (0.88- (0.86- (0.88-      2.37  evidence
       1.07) 1.08) 1.07)        
Palmer,  6 RCT Dialysis 2315/ RR Random 0.94 0.94 0.94 0/6/0 0.075 0.0 (0.654) 0.312 0.312 0.81- No No
    4627    (0.84- (0.84- (0.84-      1.10  evidence
       1.06) 1.06) 1.06)        
Navaneethan,  4 RCT Dialysis 906/ RR Random 0.96 0.96 0.89 0/4/0 0.460 27.1 (0.249) 0.817 0.242 0.28- No No
et al 2009    1839   (0.65- (0.65- (0.73-      3.30  evidence
       1.40) 1.40) 1.08)        
Strippoli,  3 RCT CKD and dialysis 696/ RR Random 0.83 0.83 0.83 0/3/0 0.027 0.0 (0.672) 0.078 0.078 0.21- Yes No
et al 2008     1404    (0.67- (0.67- (0.67-      3.33  evidence
       1.02) 1.02) 1.02)        
Combined 8 RCT Dialysis – RR – – 0.98  0.98 0/8/0 0.259 0.0 (0.559) 0.644 9,644 0.88- No No
Analysis        (0.89- (0.89-      1.09  evidence
        1.08) 1.08)        
CKD, chronic kidney disease; D/N/I, Decreasing risk/No difference/Increasing risk; F, fixed effect; HR, hazard ratio; N, number of studies; NA, not applicable; N/T, number of intervention/
total; PI, prediction intervals; R, random effect; RCT, randomized controlled study; RR, risk ratio; S, small-study effect; T, type of studies; T/M, Type of metrics; *Value reported in 
original article of the meta-analysis; §Value obtained from re-analysis of original meta-analysis.
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Table V. Effects of statin therapy among kidney transplant recipients (all-cause mortality).
 Author/       Effect Random Fixed  Egger’s I2 p-value p-value 95%
 year N T Type of patients N/T T/M Model* size* effect§ effect§ D/N/I p-value (p-value) (R) (F) PI S Evidence
Rostami,  5 RCT, Kidney transplant 6973/ HR Random 0.75 0.76 0.78 4/2/0 0.033 48.3 0.001 < 0.001 0.48- Yes Weak
et al 2017   OS recipient 13916   (0.63- (0.64- (0.69-   (0.085)   1.18  
       0.88) 0.89)  0.87)         
Palmer,  6 RCT Kidney transplant 1382/ RR Random 1.08 1.08 1.05 0/6/0 0.475 9.0 (0.359) 0.783 0.680 0.36- No No
et al 2014    recipients 2760   (0.63- (0.63- (0.80-      3.22  evidence
       1.83) 1.84) 1.30)        
Navaneethan,  4 RCT Kidney transplant 1542/ RR Random 1.30 1.30 1.06 0/4/0 0.313 31.2 (0.225) 0.558 0.609 0.06- No No
et al 2009    recipients 3045    (0.54- (0.54- (0.85-      26.88  evidence
       3.12) 3.11)  1.31)      
Strippoli, 4 RCT Kidney transplant  1309/ RR Random 1.30 1.30 1.06 0/4/0 0.313 31.2 (0.225) 0.558 0.609 0.06- No No
   recipients 2619    (0.54- (0.54- (0.85-      26.88  evidence
       3.12) 3.11) 1.31)        
Combined 14 Comb- Kidney transplant – RR – – 0.84 0.86 4/10/0 0.392 50.7 (0.015) 0.03 0.001 0.54- No Weak
Analysis  ined  recipients     (0.72- (0.79-      1.30
        0.98) 0.94)       
D/N/I, decreasing risk/No difference/Increasing risk; F, fixed effect; HR, hazard ratio; N, number of studies; NA, not applicable; N/T, number of intervention/total; OS; observational 
study; PI, prediction intervals; R, random effect; RCT, randomized controlled study; RR, risk ratio; S, small-study effect; T, type of studies; T/M, Type of metrics; *Value reported in the 
original article of the meta-analysis; §Value obtained from re-analysis of the original meta-analysis.
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Table VI. Effects of statin therapy among kidney transplant recipients (cardiovascular mortality).
 Author/       Effect Random Fixed  Egger’s I2 p-value p-value 95%
 year N T Type of patients N/T T/M Model* size* effect§ effect§ D/N/I p-value (p-value) (R) (F) PI S Evidence
Palmer,  4 RCT Kidney transplant 1161/ RR Random 0.68 0.68 0.68 0/4/0 0.421 0.0 (0.559) 0.057 0.057 0.28- No No
et al 2014   recipients 2322   (0.45- (0.45- (0.45-      1.63  evidence
        1.01) 1.01) 1.01)        
Navaneethan,  3 RCT Kidney transplant  1360/ RR Random 0.68 0.69 0.69 0/3/0 0.356 0.0 (0.395) 0.067 0.067 0.05- No No
et al 2009   recipients 2681   (0.46- (0.46- (0.46-      9.54  evidence
        1.03) 1.03) 1.03)        
Strippoli,  3 RCT Kidney transplant  1127/ RR Random 0.68 0.69 0.69 0/3/0 0.356 0.0 (0.395) 0.067 0.067 0.05- No No
et al 2008   recipients 2255   (0.46- (0.46- (0.46-      9.54  evidence
        1.03) 1.03) 1.03)       
Combined 5 RCT Kidney transplant  – RR – – 0.67 0.67 0/5/0 0.398 0.0 (0.723) 0.007 0.007 0.42- No Suggestive
Analysis    recipients     (0.50- (0.50-      1.08  
        0.90) 0.90)        
D/N/I, decreasing risk/No difference/Increasing risk; F, fixed effect; N, number of studies; NA, not applicable; N/T, number of intervention/total; OS; observational study; PI, prediction 
intervals; R, random effect; RCT, randomized controlled study; RR, risk ratio; S, small-study effect; T, type of studies; T/M, Type of metrics; *Value reported in original article of the 
meta-analysis; §Value obtained from re-analysis of original meta-analysis.
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and five (36%) studied cardiovascular mortality 
in CKD%D patients. Also, the number of me-
ta-analyses that examined the effect of statin 
therapy on all-cause mortality was four (29%) 
and cardiovascular mortality was three (21%) in 
kidney-transplant recipients. 
The Effect of Statin on Mortality and of 
CKD Patients 
The individual meta-analysis and pooled me-
ta-analysis results of the association between 
statin use and mortality among CKD patients are 
summarized in Table I, II, Figure 1, and Figure 
2. All meta-analyses revealed the beneficial ef-
fects of statins with convincing evidence in three 
meta-analyses, suggestive evidence in three me-
ta-analyses, and weak evidence in two meta-anal-
yses due to moderate-to-high heterogeneity and 
small-study effects. In the overall pooled analysis 
(n = 8), there was suggestive evidence of statin 
use on all-cause mortality of non-dialysis CKD 
patients (Table I and Figure 1). 
When we assessed cardiovascular mortality, 
there were three meta-analyses with convinc-
ing evidence, and two with suggestive evidence 
in favor of the benefit of statins. However, the 
pooled meta-analysis of five articles resulted in 
weak evidence for the use of statins in preventing 
cardiovascular mortality in patients with CKD 
not on dialysis due to small-study effects (Table 
II and Figure 2).
The Effect of Statin on Mortality of 
CKD Patients on Dialysis
The individual meta-analysis and pooled me-
ta-analysis results of the association between statin 
use and mortality among CKD 5D patients are 
summarized in Table III, IV, Figure 3, and Figure 4. 
When all-cause mortality was measured as an out-
come of interest, two meta-analyses indicated weak 
evidence due to large heterogeneity, and no associ-
ations were found in five of them. In the combined 
analysis (n=7), there was no supporting evidence of 
a beneficial effect of statins on all-cause mortality in 
CKD 5D (Table III and Figure 3). 
None of the five meta-analyses showed a sig-
nificant effect of statin use on cardiovascular 
mortality in CKD 5D patients. This was observed 
by pooled analysis (Table IV and Figure 4).
The Effect of Statin on Mortality Among 
Kidney Transplant Recipients
The individual meta-analysis and pooled me-
ta-analysis results of the association between statin 
Figure 1. Effects of statin therapy in CKD patients (all-
cause mortality).
Figure 2. Effects of statin therapy in CKD patients (cardio-
vascular mortality).
Figure 3. Effects of statin therapy in CKD 5D patients (all-
cause mortality).
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use and kidney transplant recipients’ mortality are 
summarized in Table V, Table VI, Figure 5, and 
Figure 6. When all-cause mortality was analyzed, 
only one meta-analysis with the type of RCTs and 
cohort studies showed weak evidence supporting 
the effect of statins. The validity is still limited due 
to a small-study effect. The other three meta-anal-
yses of RCTs showed no significant association 
between statin use and all-cause mortality. In the 
overall pooled analysis (n = 4), there was weak evi-
dence supporting the beneficial effects of statin use 
on all-cause mortality among kidney transplant 
recipients (Table V and Figure 5).
The cardiovascular mortality of kidney trans-
plant recipients and statin therapy included three 
meta-analyses, and they all showed no evidence 
of the preventive role of statins. Combined anal-
ysis (n = 3) revealed suggestive evidence for the 
effect of statin treatment in preventing cardiovas-
cular mortality in patients who had undergone 
kidney transplantation (Table VI and Figure 6).
Discussion
We identified and comprehensively analyzed 
32 meta-analyses from 14 articles. While 24 as-
sociations were statistically significant, only 11 of 
them were corroborated by convincing evidence 
from RCTs. In meta-analyses, statin showed sug-
gestive and weak evidence for an association with 
beneficial effects on all-cause and cardiovascular 
mortality in CKD patients, respectively. For kid-
ney-transplant patients, statins showed weak and 
suggestive evidence for reduced all-cause and 
cardiovascular mortality, respectively. However, 
in dialyzed patients, combined analyses showed 
no beneficial effects of statins on all-cause and 
cardiovascular mortality.
Patients with CKD are considered to be at high 
or very high risk of atherosclerotic cardiovascular 
disease according to 2019 ESC guidelines, and the 
use of statins or the statin/ezetimibe combination 
is recommended in non-dialyzed CKD patients 
with a high level of evidence29. However, two 
major RCTs (the Die Deutsche Diabetes Dialyse 
Studies (4D) trial and a study to evaluate the use 
of rosuvastatin in subjects on regular hemodialy-
sis an assessment of survival and cardiovascular 
events (AURORA) trial) fail to show a significant 
reduction in cardiovascular mortality in patients 
on hemodialysis30,31. There are no RCTs on peri-
toneal dialysis patients. Some observational stud-
Figure 4. Effects of statin therapy in CKD 5D patients 
(cardiovascular mortality).
Figure 5. Effects of statin therapy among kidney trans-
plant recipients (all-cause mortality).
Figure 6. Effects of statin therapy among kidney trans-
plant recipients (cardiovascular mortality).
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ies showed that statin therapy reduced all-cause 
mortality in hemodialysis patients32,33. However, 
meta-analyses and guidelines do not recommend 
statins or statin/ezetimibe combination initiation 
in dialysis-dependent CKD patients14,21,29,34. Our 
study confirmed that in patients, on hemodialysis, 
statin use was correlated with neither a reduction 
in all-cause nor cardiovascular mortality19,21,24-26,35. 
However, further evidence is required to establish 
a protective correlation between these specific 
effects of patients on hemodialysis.
It is well proven in the scientific and medical 
community that dyslipidemia contributes to the 
development of cardiovascular disease in CKD 
patients36. Cardiovascular disease is the leading 
cause of mortality in patients with CKD, with 
a majority of these patients also suffering from 
hypertension and type 2 diabetes mellitus37. 
The mechanism of action of statins, in princi-
ple, consists of reducing endothelial dysfunction 
and decreases abnormal permeability to plasma 
proteins38. Interestingly, although not the sub-
ject of this study, we did not observe a signif-
icant increase in the adverse or side effects of 
statins, such as rhabdomyolysis, hepatotoxicity, 
and cancer, among CKD patients20,24. Therefore, 
our findings are in conformance with the current 
Kidney Disease: Improving Global Outcomes 
(KDIGO) Guideline for Lipid Management in 
Chronic kidney disease (2013). The following 
guidelines recommend statin treatment for all 
CKD patients aged ≥ 50 years and not on dial-
ysis or going for kidney transplantation (GFR 
categories G1-5). Our data provide further evi-
dence in support of these recommendations. For 
CKD patients aged 18-49 years, statin treatment 
is suggested only for those with additional risk 
factors, such as coronary artery disease, diabe-
tes mellitus, previous ischemic stroke, estimated 
10-year incidence of coronary death, or more 
than 10% risk of non-fatal myocardial infarc-
tion34. In the recently published guidelines by 
the European Society of Cardiology (2019) and 
American College of Cardiology (2018), patients 
with CKD were considered to be at high (CKD 
G3) or very-high (CKD G4-5) risk of atheroscle-
rotic cardiovascular disease29,39. 
As a result, ambitious and aggressive treatment 
goals were set. Such recommendations includ-
ed using statin regimens to achieves more than 
50% reductions in low-density lipoprotein (LDL) 
cholesterol from baseline for all patients with 
CKD and an LDL cholesterol goal of <55 mg/dL 
for very-high risk and <70 mg/dL for high-risk 
patients. Hence, the use of statins or the statin/
ezetimibe combination was recommended in all 
CKD patients with a Class I recommendation and 
an A level of evidence. In transplant recipients, 
statin treatment may be considered with a Class 
IIa recommendation and a B level of evidence29.
Although evidence supporting the use of statins 
in kidney transplant recipients is generally weak, 
statins had positive and protective effects. These 
findings are supported by the general medical 
community recommendation of statin use among 
patients with a transplanted kidney. In kidney 
transplant recipients, cardiovascular diseases are 
the major cause of mortality. Dyslipidemia is thus 
a common causal pathway leading to cardiovas-
cular mortality, similarly to patients with CKD40. 
This commonality may explain the protective cor-
relation of statins used in transplanted patients. 
However, the role of statins in kidney transplant 
recipients is multidimensional and affected by 
several factors. In contrast to patients with CKD, 
kidney transplant recipients are under continuous 
immunosuppressive therapy, including corticoste-
roids and calcineurin inhibitors (CNIs). Long-term 
corticosteroid and CNI use are well proven to 
increase LDL cholesterol, total cholesterol, and 
triglycerides in a dose-dependent manner41,42, ex-
plaining in part the beneficial effects of statins 
on CV mortality among these patients. Pharma-
cokinetic interaction between CNIs and statins 
should be deliberated. The Assessment of Lescol 
in Renal Transplant (ALERT) study is the major 
RCT that assessed cyclosporine interaction and 
fluvastatin43. Unlike most other statins, fluvastatin 
is not metabolized by the cytochrome P450 3A4 
(CYP3A4) enzyme. CYP3A4 is inhibited by CNIs, 
potentially leading to an increase in the bioavail-
ability of fluvastatin10,29. Therefore, when patients 
on long term immune suppression are prescribed 
statins, pharmacokinetic interactions between the 
two drugs should always be considered. Further 
pharmacologic research is necessary to establish 
safe and practical guidelines in the case of dual 
immunosuppressant regimen and statin therapy.
Our study has several limitations. We only in-
cluded meta-analyses that could be re-analyzed, 
potentially limiting our ability to control con-
founding variables that differed across the indi-
vidual studies. Additionally, individual observa-
tional studies themselves have biases, possibly 
transferring these biases into the meta-analysis 
that included those different studies. The dose-ef-
fect of statins was beyond the scope of our anal-
ysis and such was not reported in our results or 
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discussion. Similarly, combination therapies such 
as statins with ezetimibe were also beyond our re-
search and so were not performed due to a lack of 
studies and robust analysis. However, this is the 
first performed umbrella review of meta-analyses 
about statin use in CKD patients made through 
the recently published data.
Conclusions
Our umbrella review extensively re-analyzed the 
meta-analyses in search of the association between 
statin use and all-cause mortality and cardiovascu-
lar mortality, which was not analyzed in the other 
recently published umbrella review14. 6 of 15 stud-
ies showed a significantly reduced mortality among 
CKD patients. Five of eleven studies on statins and 
cardiovascular mortality were significant. The ben-
eficial effects of statin were shown in CKD patients 
not on dialysis for both all-cause mortality and car-
diovascular mortality and in kidney transplant recipi-
ents for cardiovascular mortality but not for all-cause 
mortality. For patients on dialysis, the beneficial 
effects of statin treatment could not be confirmed, 
neither for all-cause mortality nor for cardiovascular 
mortality. These results help to understanding the 
real effects of statins on CKD patients.
Conflict of Interest
The Authors declare that they have no conflict of interests.
Acknowledgements
The authors’ responsibilities were as follows- R.A.G. and 
J.I.S designed this study, G.H.J, S.Y, and C.H.H. collect-
ed data. G.H.J, C.H.H., and S.Y. did the analyses. R.A.G., 
J.Y.L., K.H.L., J.W.Y., P.G., A.K., and J.I.S wrote the first 
draft of the manuscript and gave critical comments on the 
manuscript draft. All authors had full access to all the study 
data. All authors reviewed, wrote, and approved the final 
version. The corresponding author had the ultimate respon-
sibility for the decision to submit for publication.
Funding Information
Neither financial support nor any sort of sponsorship was 
received for this study.
References
 1) Chen TK, Knicely DH, Grams ME. Chronic kidney 
disease diagnosis and management: a review. 
JAMA 2019; 322: 1294-1304.
 2) Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The in-
cidence of end-stage renal disease is increasing 
faster than the prevalence of chronic renal insuf-
ficiency. Ann Intern Med 2004; 141: 95-101.
 3) Coresh J, Selvin E, Stevens LA, Manzi J, Kusek 
JW, Eggers P, Van Lente F, Levey AS. Prevalence 
of chronic kidney disease in the United States. 
JAMA 2007; 298: 2038-2047.
 4) GBD 2017 Causes of Death Collaborators. Glob-
al, regional, and national age-sex-specific mortal-
ity for 282 causes of death in 195 countries and 
territories, 1980-2017: a systematic analysis for 
the Global Burden of Disease Study 2017. Lancet 
2018; 392: 1736-1788.
 5) Andrassy KM. Comments on ‘KDIGO 2012 clini-
cal practice guideline for the evaluation and man-
agement of chronic kidney disease’. Kidney Int 
2013; 84: 622-623.
 6) Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker 
S, Plattner B, Saran R, Wang AYM, Yang CW. 
Chronic kidney disease: global dimension and 
perspectives. Lancet 2013; 382: 260-272.
 7) GBD 2016 Disease and Injury Incidence and 
Prevalence Collaborators. Global, regional, and 
national incidence, prevalence, and years lived 
with disability for 328 diseases and injuries for 
195 countries, 1990-2016: a systematic analy-
sis for the Global Burden of Disease Study 2016. 
Lancet 2017; 390: 1211-1259.
 8) GBD 2017 Causes of Death Collaborators. Glob-
al, regional, and national age-sex specific mor-
tality for 264 causes of death, 1980-2016: a sys-
tematic analysis for the Global Burden of Disease 
Study 2016. Lancet 2017; 390: 1151-1210.
 9) Schlackow I, Kent S, Herrington W, Emberson J, 
Haynes R, Reith C, Collins R, Landray MJ, Gray 
A, Baigent C, Mihaylova B, Group SC. Cost-ef-
fectiveness of lipid lowering with statins and eze-
timibe in chronic kidney disease. Kidney Int 2019; 
96: 170-179.
10) Baigent C, Landray MJ, Reith C, Emberson J, 
Wheeler DC, Tomson C, Wanner C, Krane V, 
Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin 
A, Agodoa L, Gaziano M, Kasiske B, Walker R, 
Massy ZA, Feldt-Rasmussen B, Krairittichai U, 
Ophascharoensuk V, Fellström B, Holdaas H, Te-
sar V, Wiecek A, Grobbee D, de Zeeuw D, Grön-
hagen-Riska C, Dasgupta T, Lewis D, Herrington 
W, Mafham M, Majoni W, Wallendszus K, Grimm 
R, Pedersen T, Tobert J, Armitage J, Baxter A, 
Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, 
Simpson D, Sleight P, Young A, Collins R, Inves-
tigators S. The effects of lowering LDL cholester-
ol with simvastatin plus ezetimibe in patients with 
chronic kidney disease (Study of Heart and Renal 
Protection): a randomised placebo-controlled tri-
al. Lancet 2011; 377: 2181-2192.
11) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, 
Rutherford JD, Cole TG, Brown L, Warnica JW, 
Arnold JM, Wun CC, Davis BR, Braunwald E. 
The effect of pravastatin on coronary events af-
ter myocardial infarction in patients with aver-
Statins for CKD, dialysis patients, and kidney transplant recipients
2709
age cholesterol levels. Cholesterol and recurrent 
events trial investigators. N Engl J Med 1996; 
335: 1001-1009.
12) Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, 
Ball A, Sherrard DJ, Stehman-Breen CO. HMG-
CoA reductase inhibitors are associated with re-
duced mortality in ESRD patients. Kidney Int 
2002; 61: 297-304.
13) Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan 
G. For the cholesterol and recurrent events trial 
investigators. Pravastatin for secondary preven-
tion of cardiovascular events in persons with mild 
chronic renal insufficiency. Ann Intern Med 2003; 
138: 98-104.
14) He Y, Li X, Gasevic D, Brunt E, McLachlan F, Mil-
lenson M, Timofeeva M, Ioannidis JPA, Camp-
bell H, Theodoratou E. Statins and multiple non-
cardiovascular outcomes: umbrella review of me-
ta-analyses of observational studies and random-
ized controlled trials. Ann Intern Med 2018; 169: 
543-553.
15) Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Sal-
ari P, Ray KK, Pencina MJ, Rizzo M, Rysz J, Ab-
dollahi M, Nicholls SJ, Banach M. Statins de-
crease all-cause mortality only in CKD patients 
not requiring dialysis therapy--a meta-analysis of 
11 randomized controlled trials involving 21,295 
participants. Pharmacol Res 2013; 72: 35-44.
16) Messow CM, Isles C. Meta-analysis of statins in 
chronic kidney disease: who benefits? QJM 2017; 
110: 493-500.
17) Navaneethan SD, Pansini F, Perkovic V, Manno C, 
Pellegrini F, Johnson DW, Craig JC, Strippoli GFM. 
HMG CoA reductase inhibitors (statins) for people 
with chronic kidney disease not requiring dialysis. 
Cochrane Database Syst Rev 2009; 2: CD007784.
18) Navaneethan SD, Perkovic V, Johnson DW, Nig-
wekar SU, Craig JC, Strippoli GF. HMG CoA re-
ductase inhibitors (statins) for kidney transplant 
recipients. Cochrane Database Syst Rev 2009; 2: 
CD005019.
19) Navaneethan SD, Shrivastava R. HMG CoA re-
ductase inhibitors (statins) for dialysis patients. 
Cochrane Database Syst Rev 2004; 4: CD004289.
20) Palmer SC, Navaneethan SD, Craig JC, Johnson 
DW, Perkovic V, Hegbrant J, Strippoli GFM. HMG 
CoA reductase inhibitors (statins) for people with 
chronic kidney disease not requiring dialysis. Co-
chrane Database Syst Rev 2014; 5: CD007784.
21) Palmer SC, Navaneethan SD, Craig JC, Johnson 
DW, Perkovic V, Nigwekar SU, Hegbrant J, Strip-
poli GFM. HMG CoA reductase inhibitors (statins) 
for dialysis patients. Cochrane Database Syst 
Rev 2013; 9: CD004289.
22) Palmer SC, Navaneethan SD, Craig JC, Perkovic 
V, Johnson DW, Nigwekar SU, Hegbrant J, Strip-
poli GF. HMG CoA reductase inhibitors (statins) 
for kidney transplant recipients. Cochrane Data-
base Syst Rev 2014; 1: CD005019.
23) Rostami Z, Moteshaker Arani M, Salesi M, Safia-
badi M, Einollahi B. Effect of statins on patients 
and graft survival in kidney transplant recipients: 
a survival meta-analysis. Iran J Kidney Dis 2017; 
11: 329-338.
24) Strippoli GFM, Navaneethan SD, Johnson DW, 
Perkovic V, Pellegrini F, Nicolucci A, Craig JC. Ef-
fects of statins in patients with chronic kidney dis-
ease: meta-analysis and meta-regression of ran-
domised controlled trials. BMJ 2008; 336: 645-651.
25) Sun L, Zou L, Chen M, Liu B. Meta-analysis of 
statin therapy in maintenance dialysis patients. 
Ren Fail 2015; 37: 1149-1156.
26) Yang M, Xie XS, Yuan WJ. A meta-analysis of 
the effects of statin treatment on cardiovascular 
events and all-cause mortality in diabetic dialysis 
patients. Int J Clin Exp Med 2015; 8: 8415-8424.
27) Zhang X, Xiang C, Zhou YH, Jiang A, Qin YY, He 
J. Effect of statins on cardiovascular events in pa-
tients with mild to moderate chronic kidney dis-
ease: a systematic review and meta-analysis of 
randomized clinical trials. BMC Cardiovasc Dis-
ord 2014; 14: 19-19.
28) Zhang Z, Wu P, Zhang J, Wang S, Zhang G. The 
effect of statins on microalbuminuria, proteinuria, 
progression of kidney function, and all-cause 
mortality in patients with non-end stage chronic 
kidney disease: a meta-analysis. Pharmacol Res 
2016; 105: 74-83.
29) Mach F, Baigent C, Catapano AL, Koskinas KC, 
Casula M, Badimon L, Chapman MJ, De Back-
er GG, Delgado V, Ference BA, Graham IM, 
Halliday A, Landmesser U, Mihaylova B, Ped-
ersen TR, Riccardi G, Richter DJ, Sabatine MS, 
Taskinen MR, Tokgozoglu L, Wiklund O, Group 
ESCSD. 2019 ESC/EAS Guidelines for the man-
agement of dyslipidaemias: lipid modification to 
reduce cardiovascular risk. Eur Heart J 2020; 41: 
111-188.
30) Fellström BC, Jardine AG, Schmieder RE, 
Holdaas H, Bannister K, Beutler J, Chae DW, 
Chevaile A, Cobbe SM, Grönhagen-Riska C, De 
Lima JJ, Lins R, Mayer G, McMahon AW, Parving 
HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci 
D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, 
Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, 
Zannad F, Group AS. Rosuvastatin and cardio-
vascular events in patients undergoing hemodial-
ysis. N Engl J Med 2009; 360: 1395-1407.
31) Wanner C, Krane V, März W, Olschewski M, 
Mann JF, Ruf G, Ritz E. Atorvastatin in patients 
with type 2 diabetes mellitus undergoing hemodi-
alysis. N Engl J Med 2005; 353: 238-248.
32) Mason NA, Bailie GR, Satayathum S, Bragg-Gresh-
am JL, Akiba T, Akizawa T, Combe C, Rayner HC, 
Saito A, Gillespie BW, Young EW. HMG-coen-
zyme a reductase inhibitor use is associated with 
mortality reduction in hemodialysis patients. Am J 
Kidney Dis 2005; 45: 119-126.
33) Jung J, Bae GH, Kang M, Kim SW, Lee DH. 
Statins and all-cause mortality in patients under-
going hemodialysis. J Am Heart Assoc 2020; 9: 
e014840.
34) Tonelli M, Wanner C; Kidney Disease: Improv-
ing Global Outcomes Lipid Guideline Devel-
R.A. Ghayda, J.Y. Lee, J.W. Yang, C.H. Han, G.H. Jeong, et al
2710
opment Work Group M. Lipid management in 
chronic kidney disease: synopsis of the kidney 
disease: improving global outcomes 2013 clin-
ical practice guideline. Ann Intern Med 2014; 
160: 182-182.
35) Gluba A, Rysz J, Banach M. Statins in patients 
with chronic kidney disease: why, who and when? 
Expert Opin Pharmacother 2010; 11: 2665-2674.
36) Drüeke TB, Nguyen Khoa T, Massy ZA, Witko-Sar-
sat V, Lacour B, Descamps-Latscha B. Role of oxi-
dized low-density lipoprotein in the atherosclerosis 
of uremia. Kidney Int Suppl 2001; 78: S114-S119.
37) Banach M, Mikhailidis DP, Kjeldsen SE, Rysz 
J. Time for new indications for statins? Med Sci 
Monit 2009; 15: MS1-MS5.
38) O’Driscoll G, Green D, Taylor RR. Simvastatin, an 
HMG-coenzyme A reductase inhibitor, improves 
endothelial function within 1 month. Circulation 
1997; 95: 1126-1131.
39) Grundy SM, Stone NJ, Bailey AL, Beam C, Birt-
cher KK, Blumenthal RS, Braun LT, de Ferran-
ti S, Faiella-Tommasino J, Forman DE, Goldberg 
R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-
Jones D, Lopez-Pajares N, Ndumele CE, Orrin-
ger CE, Peralta CA, Saseen JJ, Smith SC, Jr, 
Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/
AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/AS-
PC/NLA/PCNA Guideline on the Management of 
Blood Cholesterol: a report of the American Col-
lege of Cardiology/American Heart Association 
Task Force on Clinical Practice Guidelines. Cir-
culation 2019; 139: e1082-e1143.
40) Jardine AG, Gaston RS, Fellstrom BC, Holdaas 
H. Prevention of cardiovascular disease in adult 
recipients of kidney transplants. Lancet 2011; 
378: 1419-1427.
41) Vaziri ND. Dyslipidemia of chronic renal failure: 
the nature, mechanisms, and potential conse-
quences. Am J Physiol Renal Physiol 2006; 290: 
F262-F272.
42) Holdaas H, Fellström B, Jardine AG, Nyberg G, 
Grönhagen-Riska C, Madsen S, Neumayer HH, 
Cole E, Maes B, Ambühl P, Logan JO, Staffler 
B, Gimpelewicz C, Group AS. Beneficial effect 
of early initiation of lipid-lowering therapy follow-
ing renal transplantation. Nephrol Dial Transplant 
2005; 20: 974-980.
43) Fellström B, Holdaas H, Jardine AG, Holme I, Ny-
berg G, Fauchald P, Grönhagen-Riska C, Mad-
sen S, Neumayer H-H, Cole E, Maes B, Ambühl 
P, Olsson AG, Hartmann A, Logan JO, Peder-
sen TR, Assessment of Lescol in Renal Trans-
plantation Study I. Effect of fluvastatin on renal 
end points in the Assessment of Lescol in Re-
nal Transplant (ALERT) trial. Kidney Int 2004; 66: 
1549-1555.
